Navigation Links
MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
Date:2/28/2008

MAP0004 demonstrated pain relief in 32% of patients at ten minutes,

pain relief in 72% of patients at two hours, and sustained pain relief

in 43% of patients at 24 hours in a treatment received population.

The trial also showed clinically significant trends in the resolution

of phonophobia, photophobia and nausea at certain time points.

MAP0004 was shown in the trial to be well tolerated and no serious

adverse events were reported.

-- Conducted end of Phase 2 meetings with the U.S. Food and Drug

Administration for UDB and MAP0004 in preparation for the initiation

of Phase 3 clinical programs.

-- Initiated a Phase 2a clinical trial of MAP0005 for the potential

treatment of asthma and chronic obstructive pulmonary disease.

MAP0005 combines a corticosteroid and a long-acting beta-agonist

within a single particle, and is administered via the company's

proprietary Tempo(TM) inhaler.

-- Added experienced pharmaceutical industry executives to its management

team and board of directors. Charlene A. Friedman was appointed Vice

President, General Counsel and Secretary, and Shashidar Kori, M.D. was

appointed Vice President of Clinical Development. Also, Bernard J.

Kelley, former President, Merck Manufacturing Division, Merck & Co.,

Inc., was appointed to the board of directors.

-- Completed its initial public offering and a Series D equity financing,

raising combined gross proceeds of approximately $119 million to

further support research and development.

"In 2007, positive results in two Phase 2 programs allowed us to focus our resources on planning for the advancement of our pediatric asthma and migraine drug candidates into late-stage clinical trials," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals.
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- As kids transition from ... of cyberbullies, according to a recent study. ... through 8 found that verbal and physical bullying declines ... bullying intervention and prevention strategies must address all types ... boys and girls, the researchers said. The study was ...
(Date:9/19/2014)... Visiting Nurse Association (VNA) Health Group, ... hospice and palliative care and community-based care, was honored ... yesterday at the New York Stock Exchange. , Founded ... entrepreneur to care for immigrant families suffering from tuberculosis ... to meet the urgent healthcare needs of the communities ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Lipitor lawsuits ... caused some patients to develop Type 2 diabetes continue ... underway in U.S. District Court, District of South Carolina, ... issued on September 12, 2014, discovery is underway and ... report noted that Pfizer, Inc., the manufacturer of Lipitor, ...
(Date:9/19/2014)... 2014) - New research published today in the online ... could reach 6,800 in West Africa by the end ... enacted. , Arizona State University and Harvard University ... of rise in cases significantly increased in August in ... quarantine was put in place, indicating that the mass ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Research predicts possible 6,800 new Ebola cases this month 2
... is one of the leading causes of blindness. The cause ... raised pressure within the eye, (the intraocular pressure), that can ... damage results in poor blood supply or weak end eye ... the optic nerve leading to the brain. Fluid enters and ...
... imaging test may identify patients with the gene mutation ... Doppler tissue imaging (DTI) as a more powerful way ... Hypertrophic cardiomyopathy (HCM) causes thickening of the left ventricle ... of sudden cardiac death in the young, affecting one ...
... recent study, the researchers confirmed that people who consume high ... lungs. And for the first time, the research showed that ... decline in lung function over time.// Just like an apple ... may help keep lung disease away, according this new research. ...
... makes detection more easier. A combined scanner detects more ... method. It is notoriously difficult to get an accurate ... is dense and so it's not always possible to ... at the University of Texas now say that combining ...
... to a recent study, a rare genetic condition has uncovered ... unusual childhood genetic disorder marked by bone marrow failure. If ... of a number of cancers, including brain, head and neck, ... and the Children's Hospital, Boston, have been studying a number ...
... Hormone replacement in patch form improves mood and libido ... difficulty reaching orgasm and painful intercourse. They assume it's ... no licensed treatment for these symptoms. ,But a ... California reveals that the patch form of hormone replacement ...
Cached Medicine News:Health News:Vitamin C maintains healthy lungs 2
(Date:9/19/2014)... Sept. 19, 2014 Five MinuteClinic walk-in medical clinics are ... metropolitan area. Three clinics opened in Memphis ... fourth clinic will be added in Springfield ... is expected to open October 22.  MinuteClinic is the ... the United States . The ...
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
(Date:9/19/2014)... 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: BSTC ... marketed as XIAFLEX ® in the U.S. and XIAPEX ... Tom Wegman , will present a corporate overview at ... Industry Conference. The presentation will take place ... the Millennium Broadway Hotel in New York, NY ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... NEW YORK, May 25, 2011 ... research report is available in its ... Devices Market Outlook in United Kingdom ... Devices, Infusion Systems, Central Venous Catheters ...
... May 25, 2011 Reportlinker.com announces that ... in its catalogue: Triple ... http://www.reportlinker.com/p0284714/Triple-Analysis-Lymphoma-Pancreatic-Cancer-and-Prostate-Cancer.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... drug development strategies in Lymphoma, Pancreatic Cancer ...
Cached Medicine Technology:Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 2Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 3Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 4Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 5Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 6Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 7Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 8Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 9Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 10Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 11Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 12Reportlinker Adds Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer 2Reportlinker Adds Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer 3Reportlinker Adds Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer 4Reportlinker Adds Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer 5
... 1064 is a laser system with one single ... maximum continuous intensities of either 60 W or ... in all-mini-invasive surgical techniques. This laser is the ... the most requested from hospitals and clinics which ...
Smart Chill is a compact cooling system that provides intense localised skin cooling through a comfortable contact handpiece....
... been designed exclusively for vascular treatments, Smart VS ... range which ensures fast amortisation of the investment ... can be fitted with a polarised light viewing ... to be treated as well as the operators ...
... Erbium (Er:YAG) laser is the ideal instrument ... Smart 2940 Plus, the majority of surface ... a wide range of scar tissue, with ... most cases with the elimination of anaesthetics, ...
Medicine Products: